Home / Oncology (page 162)

Oncology

AbbVie Completes $21 Billion Acquisition of Pharmacyclics

AbbVie has completed its $21 billion acquisition of Pharmacyclics, Inc., strengthening its oncology portfolio. The company said that it has completed the acquisition of Pharmacyclics, a leader in the hematological oncology market with its blockbuster drug Imbruvica (ibrutinib). Imbruvica is a first-in-class BTK-inhibitor used to treat hematological cancers, a $24 …

Read More »

Bluebird Bio Enters CAR T Deal with Five Prime

Bluebird bio announced that it has entered into an immuno-oncology deal with Five Prime Therapeutics. The companies said that they have entered into an exclusive license agreement to research, develop and commercialize chimeric antigen receptor (CAR) T cell therapies. Under the agreement, the companies will use Five Prime’s proprietary human …

Read More »

Biodesix Launches its Liquid Biopsy Mutation Test for Lung Cancer Patients

Biodesix, Inc. has launched its targeted liquid biopsy mutation test for patients with advanced lung cancer. The molecular diagnostics company announced the launch of GeneStrat, a targeted liquid biopsy mutation test for genotyping tumors of patients with advanced non-small cell lung cancer (NSCLC). The results from the blood test are …

Read More »

Novartis’ Afinitor Meets its Primary Endpoint in a Late-Stage Study in Patients with NET

Novartis’ cancer drug Afinitor extended progression-free survival (PFS) in a late-stage study of patients with advanced nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin, paving the way for an expanded indication. The company said that the Phase III RADIANT-4 study Afinitor (everolimus) tablets plus best supportive care in …

Read More »

Genentech’s Investigational Immunotherapy Doubles Survival in Mid-Stage Lung Cancer Trial

Roche’s Genentech recently announced that its investigational immunotherapy doubled the likelihood of survival in lung cancer patients with the highest level of a specific biomarker. Genentech, a member of the Roche Group, announced interim results from its mid-stage study in patients with previously treated non-small cell lung cancer (NSCLC). According …

Read More »

FDA Fast Tracks Merck KGaA’s Pancreatic Cancer Candidate

The US Food and Drug Administration (FDA) has granted Fast Track designation to Merck KGaA and partner Threshold Pharmaceuticals’ investigational pancreatic cancer drug. The companies won Fast Track status for the development of evofosfamide, administered in combination with gemcitabine, for the treatment of previously untreated patients with metastatic or locally …

Read More »

Lilly Enters Research Deal with BioNTech for New Cancer Immunotherapies

Pharma giant Eli Lilly and Company is teaming up with Germany-based BioNTech to discover novel cancer immunotherapies. The companies have entered into a research collaboration to discover new cancer drugs, which use the body’s own immune system to attack cancer cells and create possible new treatment options for patients with …

Read More »

FDA Clears Roche’s KRAS Mutation Test for Colorectal Cancer Patients

Today, Roche announced that US health regulators have approved its diagnostic test for a certain gene mutation in patients with advanced colorectal cancer. The company said that the US Food and Drug Administration (FDA) approved the cobas KRAS Mutation Test for diagnostic use. The real-time polymerase chain reaction (PCR) test …

Read More »

Two Biocon Biosimilars Enter Late-Stage Studies

Asia’s Biocon recently announced an update on clinical progress of its programs, saying that two of its biosimilar candidates have entered late-stage studies. The company has partnered with Britain’s Mylan on these two molecules. The companies’ pegfilgrastim (PEG-G-CSF) and Adalimumab have entered global Phase III clinical trials, which will assess …

Read More »